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Abstract
Background: Patients’ values and preferences are fundamental tenets of evidence-based practice, yet current
osteoporosis (OP) clinical guidelines pay little attention to these issues in therapeutic decision making. This may be
in part due to the fact that few studies have examined the factors that influence the initial decision to take OP
medication. The purpose of our study was to examine patients’ experiences with the decision to take OP
medication after they sustained a fracture.
Methods: A phenomenological qualitative study was conducted with outpatients identified in a university
teaching hospital fracture clinic OP program. Individuals aged 65+ who had sustained a fragility fracture within 5
years, were ‘high risk’ for future fracture, and were prescribed OP medication were eligible. Analysis of interview
data was guided by Giorgi’s methodology.
Results: 21 patients (6 males, 15 females) aged 65-88 years participated. All participants had low bone mass; 9 had
OP. Fourteen patients were taking a bisphosphonate while 7 patients were taking no OP medications. For 12
participants, the decision to take OP medication occurred at the time of prescription and involved minimal
contemplation (10/12 were on medication). These patients made their decision because they liked/trusted their
health care provider. However, 4/10 participants in this group indicated their OP medication-taking status might
change. For the remaining 9 patients, the decision was more difficult (4/9 were on medication). These patients
were unconvinced by their health care provider, engaged in risk-benefit analyses using other information sources,
and were concerned about side effects; 7/9 patients indicated that their OP medication-taking status might change
at a later date.
Conclusions: Almost half of our older patients who had sustained a fracture found the decision to take OP
medication a difficult one. In general, the decision was not considered permanent. Health care providers should be
aware of their potential role in patients’ decisions and monitor patients’ decisions over time.
Background
Individuals who are 65+ years and have sustained a fra-
gility fracture are at increased risk for future fracture
[1-4] and should be investigated for underlying osteo-
porosis (OP) [1,2]. If bone densitometry confirms
reduced bone mass, and thus high risk for fracture if
untreated, antiresorptive medication should be
considered to reduce this fracture risk [1,2]. However,
once OP medication is prescribed, its effectiveness
depends primarily on patient adherence. There is an
abundance of literature to suggest that in real world set-
tings, treatment adherence in OP patients after a frac-
ture is low [5-9]. For example, up to 58% of patients
with a fracture who have an indication for treatment
(low bone density on bone densitometry) and have been
recommended OP medication by a physician are not
taking an antiresorptive medication at 6 months follow-
ing the recommendation [8]. Further, approximately
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been screened through a post-fracture OP intervention
discontinue the medication within 12 months of initiat-
ing it [10].
Patients’ values and preferences are fundamental
tenets of evidence-based practice, yet current OP clinical
practice guidelines pay little attention to these issues in
therapeutic decision making [11]. This may be in part
due to the fact that few studies have examined the fac-
tors that influence the initial decision to take OP medi-
cation. One study investigated preferences in older
women by presenting them with a description of differ-
ent OP medications and found that side effects and the
cost of medication were factors considered by women
when they discussed treatment selection and medication
use [12]. However, the study was conducted in a com-
munity sample of women who were not on treatment
for OP but were rather taking medication for other con-
ditions (e.g. arthritis, cardiovascular disease). Conversely,
Weiss and colleagues [13] found that effectiveness was
ranked as the most important determinant of preference
in women with, or at risk for, OP when they were pre-
sented with attributes of various OP medications (e.g.
effectiveness, dosing regimen, how long the drug had
been on the market). The purpose of our study was to
investigate patients’ experiences with the actual decision
to take prescribed OP medication after being screened
post-fracture for OP in a university teaching hospital.
Methods
Study Design
The experience of decision-making lends itself to a phe-
nomenological study [14,15]. Phenomenology is a quali-
tative approach where individuals are asked to focus on
a specific situation that they actually experienced and to
describe it in sufficient detail so that new knowledge
about the phenomenon can be obtained [16]. Specifi-
cally, an eidetic phenomenological study was conducted
which assumes there are structures, or commonalities,
to patients’ experiences regarding their decision to take
OP medication [15]. The purpose of this type of inquiry
is to describe this common structure based on a diver-
sity of experiences [14].
Recruitment
Using phenomenological methods, the meaning of the
decision to take medication was examined using
accounts of individuals who had “lived through” this
experience [17]. Sampling was purposeful and included
male and female patients who had sustained a fracture,
were prescribed OP medication, and were able to articu-
late their experiences (e.g. did not demonstrate cognitive
impairment). Participants were identified from among
patients screened by a coordinator through a fracture
clinic OP screening program [18] at an urban teaching
hospital. Eligibility criteria were English-speaking outpa-
tients aged 65+ with, or without, a history of OP treat-
ment who had sustained a fragility fracture in the last 5
years, were deemed “high risk” for future fracture based
on age, sex, prior fracture, and BMD values [19], and
were prescribed OP medication. The Ontario Drug Ben-
efit plan covers OP medication for individuals aged 65+
so cost of treatment was not a barrier to accepting treat-
ment for our sample.
Patients who met our eligibility criteria were asked by
the coordinator if they were interested in participating in
a study on post-fracture care. Study staff contacted those
who agreed. Study approval was obtained from the hospi-
tal’s Research Ethics Board. All patients gave their
informed consent prior to their inclusion in the study.
Data Collection
Data were collected through face-to-face semi-struc-
tured interviews in patients’ homes. If a home interview
was not convenient, the patient was interviewed in the
researcher’s office, or by telephone. Interviews were 1-2
hours in duration and were audiotaped. Referring to an
interview guide (see Table 1), the interviewer asked the
patient to talk about their fracture and their experience
in the fracture clinic. Patients were then asked about
recommendations for their bone health received by spe-
cialists/general practitioners (GPs) as well as their
responses to recommendations.
Consistent with the concept of “bracketing” in eidetic
phenomenology (the setting aside of one’sj u d g m e n t s ,
biases, and preconceived ideas about the phenomenon)
[20-23], the interviewer remained as neutral as possible
throughout the interview and did not reinforce or dis-
courage any topics discussed related to OP medication
use. For example, patients often discussed recommenda-
tions and experiences regarding general bone health
management, not only medication use.
All interviews were taped with a digital recorder and
detailed notes were taken. Interviews were transcribed
and downloaded in NVivo 7 [24], a qualitative software
program with flexible features that helped organize,
code, and retrieve data. Patient’sa g e ,s e x ,b o n ed e n s i t o -
metry T-scores (at the total hip, femoral neck, and L1-
L4), fracture type, fracture history, time since most
recent fracture, and OP medication status were
recorded. While we report each patient’s age and sex
and bisphosphonate use, we have only described fracture
type, T-score, and time since fracture for the group as a
whole in order to protect participants’ identities.
Data Analysis
Two researchers (JS, LF) coded all transcripts to pro-
mote a comprehensive examination of the data. These
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tent of the interview and to revise the interview guide in
order to capture additional topics of interest. Data ana-
lysis was guided by Giorgi’s methodology [25,26]. Analy-
sis began after the first interview and was an iterative
process with “meaning units” (codes) identified immedi-
ately and then revised as more interviews were con-
ducted. A coding template was developed; after six
revisions, the two researchers agreed on a final template.
Interrelationships among codes were examined and a
common structure of the decision to take OP medica-
tion was synthesized. Direct quotations from the tran-
scripts illustrated our findings.
Consistent with the phenomenological concept of
“imaginative variation” [20,21], multiple thematic possi-
bilities were considered during analysis. Discussion of
these themes occurred at the level of the larger research
team. The funding source had no role in this study.
Results
Thirty patients were identified and 21 (6 males, 15
females) consented to participate in our study. This
sample size meets recommendations for phenomenolo-
gical studies [14,27]. Reasons for not participating
included too ill (n = 2), not interested (n = 6), and car-
ing for a sick spouse (n = 1). Consistent with qualitative
research, five patients were interviewed a second time
by telephone to clarify information in their transcripts,
thus yielding 26 interviews. Seventeen of the original 21
interviews were conducted in patients’ homes, 3 were
conducted in the researcher’so f f i c e ,a n d1w a sc o n -
ducted by telephone. Table 2 describes the study sample
as a whole. Participants ranged in age from 65 to 88
and fracture type included 7 wrist, 7 hip, 4 shoulder, 1
ankle, 1 patella, and 1 pelvic fracture. Time since the
most recent fracture ranged from 6-12 months (n = 12),
12-18 months (n = 7), to 2-5 years (n = 2). All partici-
p a n t sh a dl o wb o n em a s s( D X AT - s c o r e<- 1 . 0 ) ;9h a d
OP (T-score ≤ -2.5) [28,29]. There were no trends
noted in our findings between the decision to take OP
medication and age, gender or fracture location. At the
time of the interview, 14 patients were taking a bispho-
sphonate; the remaining 7 patients were taking no OP
medication.
For 12 participants, the decision to take, or not take,
OP medication was relatively easy, involved minimal
contemplation or distress, and occurred at the time the
prescription was given. Ten of these 12 patients were
taking OP medication; 1 patient had initiated and then
stopped taking OP medication and 1 patient had not
initiated OP medication (had not filled his prescription).
For 9 patients, the decision to take, or not take, OP
medication was more difficult, requiring time and con-
sideration of several factors. Four of these 9 patients
were taking OP medication while 5 patients were not
taking medication. The following section describes these
two decision categories in further detail.
Decision required minimal contemplation (’easy’ decision)
Patients in this group described the decision as an easy
one, which required minimal contemplation. For exam-
ple, one participant considered his bisphosphonate to be
a “minor medication...just more like supplements than
medication” (#20-male age 65). Patients reported making
the decision to take, or not take, medication at the time
it was prescribed for them, speaking highly of their
health care provider. Participants indicated that they
“liked” their health care provider (GP or specialist) (#9-
Table 1 Interview Guide
Interview Protocol
1. Tell me about your fracture.
2. What recommendations did you receive by your health care
provider(s) regarding your bone health after your fracture?
Probe: What was your reaction to those recommendations?
Probe: What about the medication that was prescribed to
you?
3. What are you doing about those recommendations?
4. What has your GP/specialist explained to you about your bone
health?
Probe: What is your relationship with your GP/specialist?
5. What motivates you to take/not take your OP medication?
Probe: What makes it difficult?
6. What (or who) made you decide to take/not take your
medication? Explain.
Table 2 Description of Study Sample (n = 21)
Characteristic
Age, yrs, range 65-88
Female, n (%) 15 (71)
Fracture type, n %)
Wrist 7 (33)
Hip 7 (33)
Shoulder 4 (19)
Ankle 1 (5)
Patella 1 (5)
Pelvis 1 (5)
Time since most recent fracture, n (%)
6-12 months 12 (57)
12-18 months 7 (33)
2-5 years 2 (10)
T-Score, n (%)
-1.0 to -2.4 12 (57)
≤ -2.5 9 (43)
Taking bisphosphonate at time of interview, n (%) 14 (67)
Decision to take OP medication, n (%)
“Easy” 12 (57)
“Difficult” 9 (43)
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“a great relationship” with their health care provider
(#13-female age 70), or “trusted” their health care provi-
der in prescribing the bisphosphonate (#18-female age
73, #16-female age 75, #11-male age 73). For example,
participant #11 told us that he valued his specialist’s
“expertise and judgment and follow[ed] whatever recom-
mendations he [was] given without question” even
though he did not really understand the purpose of the
OP medication. Similarly, one 82-year old male patient
who quickly decided not to take OP medication was
influenced by the opinion of his GP who he described
as “well informed”.H er e c a l l e dt h a th i sG Ph a dw a r n e d
him of the “complications” of taking OP medication,
saying that it was “no great treat...swallowing it, you
have to be careful it doesn’t lodge in your throat. You
have to be standing up or something, I forget” (#19).
In general, participants in the “easy decision” group
made their decisions based on trust in their health care
provider rather than trust in the OP medication. When
asked about the OP medication itself, participants in
this group made brief statements about the perceived
benefits of the medication as “[keeping bone] from
weakening” (#2-male age 88), providing “extra strength
for the bone” (#9-female age 68), “[preventing] further
bone loss” (#25-female age 87), or “[improving]...bone
density” (#11-male age 73). With the exception of one
patient who complained about stomach upset, patients
taking OP medication at the time of the interview who
found the decision to take an easy one did not articulate
any potential, or actual, risks of OP medication, suggest-
ing that they did not perform any risk-benefit analyses
about the medication.
Although the decision to take OP medication had
been relatively easy for all 12 participants in this cate-
gory, 4 participants indicated that their current medica-
tion status might change. Three of the 10 patients who
were taking OP medication (#2-male age 88, #6-female
age 71, and #17-male age 79) were not convinced about
their decision to take the medication, suggesting that
they might subsequently decide not to take it. For exam-
ple, one patient did not understand what the medication
was for at all and did not appear to take it regularly, “I
think from time to time there was some pill or some-
thing that I had to take with each meal or with a meal
during any one day...we aren’t always getting up in the
morning thinking about pills” (#2-male age 88). His wife
helped him with his medication regimen but she
admitted that he missed taking pills and that he often
“erred and strayed from [his] ways”. Another patient
told us she “came from an age where people [did] what
they were told”. However, a friend had informed her
that there was not much one could do to reverse the
deterioration of bone: “it doesn’t matter what you do.
There is not a lot you can do to change what happened”
(#6-female age 71).
Another participant had been diagnosed with OP 20
years previously and had his bisphosphonate prescrip-
tion refilled regularly by his GP. However, he never dis-
cussed his bone health with his GP. This participant
told us he often forgot to take his bisphosphonate
because he “couldn’t measure what [it was] doing for
[him]”. If he forgot to take it, he told us that he didn’t
worry about or “miss it” (#17-male age 79).
Similarly, one participant stopped taking prescribed
OP medication after her first prescription ran out due
to stressful life events (including a death in the family
and a change of residence) (#25-female age 87). While
she described herself as from a generation who followed
doctors’ orders without questioning them, she told us:
“when your routine is completely destroyed, when every
day...changes, it’s difficult to stay on a routine.” She indi-
cated she would probably start taking a bisphosphonate
again in the future, “Yeah,...I’mg o i n gt og e tb a c ko nt o
it [medication].”
Decision required considerable contemplation (’difficult’
decision)
Participants classified under this group described the
decision to take, or not take, OP medication as more
difficult. Four of these 9 patients were taking OP medi-
cation at the time of the interview (4 females age 70-84)
and 5 were not taking medication at the time of the
interview (1 male age 65, 4 females age 65-77). The role
of the health care provider in this group was also influ-
ential. However, while some participants trusted/
respected their health care providers, they wanted addi-
tional discussion and reported needing to be convinced
by them in order to make a decision (see Table 3). For
example, one participant stated, “he [specialist] didn’t
say anything that convinced me that I needed to take
the medication” (#22-female age 65).
Patients in this group who were taking medication
reported that their GP or specialist had been able to
influence their decision andc o n v i n c et h e mt ot a k ei t .
One 71-year old female patient told us that on her sec-
ond visit with her specialist, he answered all her ques-
tions and made everything clear, “These pills would help
build my bones and I thought all of that through...I
thought, he’s a doctor. He knows what he’st a l k i n g
about. If it’s going to help me, what am I going to do?
Just let them sit on that dresser? That would be silly.
Take them and try to get better.” (#21)
Another female patient, aged 70, with two prior frac-
tures (#10), described concerns about taking bispho-
sphonates. Her general practitioner had prescribed OP
medication following a previous BMD test but she had
been “turned off” by her physician’s attitude: “Ig o tt h e
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women on bone density medication once they were fifty
or over...So I was not convinced to take it because...I
wasn’t convinced that I needed it. Not at all.” She was
then referred to a specialist who gave her an in-depth
explanation of her condition and about the medication
itself. Following the visit with her specialist, this partici-
pant decided to take OP medication: “I felt very confi-
dent and secure once I spoke with her [the specialist] in
detail about my concerns taking the drug. I just didn’t
want to take any drug unless it was necessary. But she
explained everything so thoroughly and had information
to back it up from my charts. So she convinced me and
she said she doesn’t mainly prescribe drugs either, nor
does she like taking them herself unless it’s necessary.”
A third participant (#15-female age 84) had pre-
sented with a second fracture to the fracture clinic; she
described her specialist as “condescending and not
direct enough” and had not been able to understand
the OP medication prescription she had received after
her first fracture: “Ic o u l d n ’t make head or tail of it
and nor could my pharmacist”. She had actually left
her specialist’s office prior to completing her appoint-
ment after her first fracture. However, the second frac-
ture heightened her perception of the seriousness of
her bone health. At this point, her GP explained the
recommended treatment more clearly and threatened
that she’dh a v et os t o ps m o k i n gi fs h ed i d n ’tt a k eh e r
OP medication: “he [the GP] said you either take that
or I get you right off your smoking immediately
(laughter)”.
When patients in the ‘difficult’ decision group
remained unconvinced by their GP or specialist to take
medication, they turned to other sources of information
(e.g. friends, family, other health care professionals,
pamphlets). In general, these sources of information
resulted in a decision not to take OP medication. In
contrast to participants in the ‘easy’ decision group who
focused on the benefits of the medication, participants
in the ‘difficult’ decision group then engaged in risk-
benefit analyses that focused on concerns about poten-
tial and actual side effects (See Table 4). For example,
one 72-year old female participant was very cautious
because she had been told that bisphosphonates cause
throat cancer and she concluded that “the fact that they
want gallons and gallons of water makes me think that
it is doing harm to my throat” (#23). Another partici-
pant considered herself extremely well informed and
fully understood the severity of her OP but she had
done extensive research on the side effects of bispho-
sphonates and was “not prepared to accept them” (#24-
female age 77). Interestingly, this participant described
Table 3 Examples of the perceived role of health care providers in the decision to take OP medication
“Easy” Decision “Difficult” Decision
Taking OP medication at time of
interview
Not taking OP medication at
time of interview
Taking OP medication at time of
interview
Not taking OP medication at
time of interview
“If she [specialist] had said to me, I want
you to drink three gallons of orange
juice a day, I probably would have said,
okay”... and later, “I have considerable
respect for the man [GP] that I see” (#11)
“I find my medical doctor,
he’s good. He seems to be
well-informed...he advised me
not to take it” (#19)
“it was my second visit and he [specialist]
was every so kind. He held my hand and
he told me we can’t take any more
chances with any more fractures...and I
thought all of that through” (#21)
“he [specialist] didn’t say
anything to me that
convinced me that I needed
to take medication” (#22)
Table 4 Examples of risk/benefit analyses related to the decision to take OP medication
“Easy” Decision “Difficult” Decision
Taking OP medication at time of
interview
Not taking OP
medication at time of
interview
Taking OP medication at time of
interview
Not taking OP medication at time of
interview
Regarding her decision to take a
bisphosphonate, “It might make my
bones stronger,...or I might gain
back some bone density” (#18)
Participant understood she
was prescribed a
bisphosphonate “to
prevent further bone
loss” (#25)
“One friend of mine was asked to take
[a bisphosphonate] and she had a major
allergic reaction to it and it caused
some problems with her blood cells...A
neighbour mentioned she’d been on [a
bisphosphonate] for almost a year...and
she was having some cramping
problems in her toe” (#10)
“I did a bit of research and elected not
to go on [bisphosphonates] because I
didn’t feel I wanted to accept the side
effects. And I was certainly right...If you
look at the side effects of [the
bisphosphonate], which has now been
discontinued because of jaw necrosis...
they lose bone in the jaw...common
sense tells one that if you have to
swallow a pill and cannot lie down or
bend for half an hour because if it
lodges in the esophagus, it creates a
great deal of damage there...and does
the damage where you do not feel it
until it’s too late” (#24)
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thought was best for [her]” but it was her decision to
“reject that advice”. Yet another participant was very
anxious about taking OP medication because she had
heard that it could “disintegrate the jaw” and she wanted
to make sure she wasn’t sacrificing her jaw for her bone
health: “I want to balance everything so I’mn o td r a g -
ging down some other part of my health...We are very
long lived in my family and I could need my jaw
another thirty years” (#3-female age 67).
The non-permanent nature of the decision to take OP
medication was also evident in participants in the “diffi-
cult decision” group. One participant (#15-female age
84) who was taking a bisphosphonate at the time of the
interview was not certain if,a n dw h e n ,s h ew o u l dr e f i l l
her prescription. A month’s supply of her OP medica-
tion remained but she had been cancelling her follow-
up appointments with the specialist until she had had
time to follow other recommendations such as exercise
and calcium intake. Of the 5 patients in this group who
were not taking OP medication at the time of the inter-
view (1 male age 65, 4 females age 65-77), 3 had a his-
tory of bisphosphonate use. One 65-year old male
participant was a GP who reported experiencing severe
side effects from the bisphosphonate so he had stopped
taking it. He did not consider his low bone mass as a
serious health concern but was considering switching to
the yearly injections of bisphosphonate (#12). One
patient with OP had stopped taking two different
bisphosphonates after initiating them at separate times,
f i n d i n gt h e mb o t ht ob ev e r yi n c o n v e n i e n t :“with all of
them, you can’t lie down after for half an hour or some-
t h i n ga n dy o uh a v et od r i n kaw h o l ep i l eo fw a t e r .I n
the morning, we take our little grandson to the babysit-
ter. We’re up at 6:25 am and I don’th a v et i m ef o r
drinking gallons of water” (#23-female age 72). Despite
encouragement from her GP who was an old friend
from university, she didn’t think of her OP as a serious
health concern. Interestingly, she had been misleading
her GP to believe that a specialist at the study hospital
was looking after her bone health: “So, I think he [the
GP] thinks [the hospital] is looking after it”. This patient
acknowledged that she had not corrected her GP about
this perception.
Similarly, another participant had been urged repeat-
edly by her GP to take OP medication after she had
been first diagnosed with OP 20 years previously; she
had tried both the weekly and the yearly bisphosphonate
but had decided to stop taking both, comparing her
decision to “Russian roulette”. She had recently attended
two consultations with a specialist but still refused to
re-start the medication. However, she told us if she had
another fracture, she might reconsider taking OP medi-
cation (#24-female age 77).
Two other participants who were not taking OP medi-
cation at the time of the interview remained undecided
(2 females age 65-67) and had not yet filled their pre-
scriptions for a bisphosphonate. Participant #3 (age 67)
had experienced two fractures and her low bone mass
was a serious health concern for her; she worried that
she might break a hip. But she had allergies and was
concerned about what she “put into [her] body”.S h e
told us that she would make a decision to take OP med-
ication after consulting with her dentist (she was con-
cerned about losing bone in her jaw). The other
participant (#22-age 65) told us: “At this point, I haven’t
made the decision to take it. That’s the decision that
would be made. It’s not a decision not to take it, it
would be a decision to take.” This participant told us
that there was a possibility that she might change her
mind - “I might think differently at 70”.
Discussion
This study highlights that for over half of fracture
patients, the decision to take OP medication was an
easy one. Most of these patients were taking a bispho-
sphonate. However, the remaining patients reported that
the decision required considerable contemplation. The
role of specialists and GPs was influential both positively
and negatively in the decision to take OP medication.
Regardless of whether the decision was a difficult one or
not, many participants (n = 11 including 2 who were
undecided) indicated that this decision was not perma-
nent and that they might be persuaded to start or stop
taking medication depending on a number of
circumstances.
The role of health care providers’ influence in medica-
tion decision-making from a patient perspective is rela-
tively unexplored in OP. In other conditions, Dowell
and Hudson [30] characterized primary care patients
with a range of medication prescriptions as “passive
users”, “active users”,o r“rejectors”. They described
“passive acceptors”,m o s to fw h o mw e r ee l d e r l y ,a s
patients who ‘blindly’ followed their physician’s advice.
But their study examined medication-taking behaviour
and did not elaborate on the decision-making of
patients. In mental health, Nolan and Badger [31] illu-
strated the power of the initial physician consultation to
influence patients’ beliefs about the appropriateness of
antidepressant medication. Patients in Nolan and Bad-
ger’s study emphasized that regular follow-up, monitor-
ing, and information by their physician to review how
treatment was progressing was viewed as symbolizing
interest in their well-being.
Many of our participants complained about the side
effects (potential and actual) of their bisphosphonate
and described how these concerns influenced their deci-
sion. This finding is consistent with that of a published
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However, Brookhart et al. [33] found that the majority
of patients who stopped and re-started OP medication,
re-started the same OP medication suggesting that
actual side effects experienced may not be the most
important issue for all patients. The results of our study
suggest that perceived side effects are critical to deci-
sion-making, but that these decisions are not static.
Ongoing risk/benefit analyses may result in side effects
being perceived as acceptable or unacceptable risks. In
contrast to Weiss and colleagues [13], who found that
effectiveness and time on the market of a medication
predicted the decision by patients with, or at risk for,
OP, to consider OP medications, the majority of partici-
pants in our study did not discuss effectiveness or time
on the market as important in their decision to take OP
medication.
The non-static nature of the decision in over 50% (11/
21) of our patients is partly reassuring, while also giving
cause for concern. On the one hand, many participants
were receptive to information and, if their concerns
were addressed, often indicated they would take medica-
tion. Of concern is that patients need to be on antire-
sorptive medication for at least 6 months for decreased
fracture risk to be realized [34]. By 24 months of antire-
sorptive medication, risk of a hip fracture can be
reduced by up to 45% [35]. Our findings indicating the
non-static nature of medication decisions suggest that
the effectiveness of OP medications may be compro-
mised in many cases. These findings echo those of
other studies that find up to 58% of patients who have
an indication do not initiate antiresorptive medication
after post-fracture OP screening [8], 74% stop taking
their medication within 12 months of initiating it [10],
and many individuals take OP medication sporadically
[36]. However, of patients with and without a fracture
who stop OP medication, an estimated 30% re-start
within 6 months and 50% re-start within 2 years sug-
gesting that many patients return to OP medication
after periods of non-use [33]. We believe that greater
emphasis needs to be paid to educating individuals
about taking medication over the long term in order to
realize benefits. In addition, our findings suggest the
need for health care providers to revisit the decision
with patients to determine if ‘willingness’ has changed,
and to intervene if this is the case.
There are several implications of our study. Health
care providers should be aware of their potential influ-
ence on patients’ medication-taking decisions and recog-
nize that some patients will decide to take their
medications based solely on having a positive relation-
ship with their physician; others will need to be con-
vinced to take medication and discussions should
address potential side effects of the OP medications.
Post-fracture, patients may also be confused about other
aspects of OP medication such as duration of treatment
[37] and health care providers should be prepared to
address these misconceptions as well. Consistent with
recommendations by McCormack & Loewen [11], we
propose that patients’ values and preferences should be
incorporated into OP clinical practice guidelines in
order to involve patients in informed decision making.
It is also possible that Cranney and colleagues’ [38] OP
decision aid, that includes information about benefits
and risks of OP therapeutic options, could be applied to
patients who have had a fracture and are at high risk for
future fracture.
Our findings may also inform adherence indices such
as the mean possession ratio (MPR). Individuals who do
not refill their medications regularly may be constantly
engaging in the decision-making process to the extent
of reducing their MPR. Consequently, the labels “adher-
ent” vs. “non-adherent” to OP medication may not be a
useful indication of medication-taking behaviour
because the decision to take a bisphosphonate is not
necessarily a permanent one. Health care providers
should persist with educating patients who have not
initiated medication post-fracture or who have stopped
taking it as this decision to take medication is likely to
change in future. Finally, patients might benefit from
interventions when they experience side effects; infor-
mation on side effects may support patients’ confidence
in treatment and offset early discontinuation of OP
medication [39].
We acknowledge several limitations to our study. We
relied on self-report and did not have other corroborat-
ing information such as the health care provider per-
spective. However, we were not so much interested in
the accuracy of information but rather the decisions
made as a result of perceptions of OP and information
from other sources. We did not follow patients’ decision
making over time so our findings about the dynamic
process of the decision to take OP medication were
based on recall and predictions about future behaviour.
OP treatment includes other modalities such as calcium,
vitamin D, and falls prevention; however, we focused on
the decision to take OP medication only. While we did
not have access to patient’s pharmacy records, our study
is strengthened by the fact that the majority of the inter-
v i e w sw e r ec o n d u c t e di nt h eh o m ew h e r et h ei n t e r -
viewer was able to verify the bisphosphonate label on
patients’ medicine bottles. To further strengthen our
study, we have provided quotations in participants’ own
words to demonstrate our findings.
Conclusions
In conclusion, almost half of our patients with a fragility
fracture who were deemed at high risk for another
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Page 7 of 9fracture reported finding the decision to take OP medi-
cation a ‘difficult’ one. Regardless of whether the deci-
sion was an ‘easy’ or ‘difficult’ one, many participants
indicated that this decision was not permanent. Health
care providers should understand the different manners
in which patients make decisions to take prescribed OP
medication and their role in these decisions and they
must ensure they discuss the potential risks and benefits
of OP medication with their patients. Health care provi-
ders should also monitor patients’ acceptance of their
decisions over time as these decisions are likely to
change.
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